Melanoma Immunotherapy: How Checkpoint Inhibitors Changed Treatment and What Side Effects to Expect

Research-informed explainer — last updated April 12, 2026

Checkpoint inhibitors — drugs that release the immune system's natural brakes — have transformed stage IV melanoma from a disease with median survival under a year to one where a meaningful fraction of patients achieve long-term remission. But these treatments can trigger autoimmune reactions in any organ, and the skin is the most commonly affected site.

This article draws on research from five dermatology and dermatopathology specialists. Dr. Mario Lacouture, Medical Director of the Symptom Management Program at NYU Langone's Perlmutter Cancer Center, authored the field's most-cited characterizations of checkpoint toxicities — including immune-related dermatologic adverse events (444 citations in JAAD, 2020) and PD-1/PD-L1 toxicity patterns (1,449 citations in Annals of Oncology, 2015). Dr. Hensin Tsao, Director of the Melanoma and Pigmented Lesion Center at Massachusetts General Hospital and Professor at Harvard Medical School, co-authored the canonical AAD melanoma management guidelines and early BRAF-immunotherapy interaction research. Dr. Lyn Duncan, Professor of Pathology at Harvard, contributed landmark research on the biology of melanoma — work that explains why these tumors are uniquely sensitive to immune attack. Dr. Darrell Rigel of NYU and Mount Sinai established foundational epidemiology on melanoma detection and staging. Dr. David Polsky of NYU identified a key resistance mechanism — Apaf-1 inactivation — explaining why some patients stop responding to treatment.

Why melanoma responds to immunotherapy

Melanoma carries one of the highest mutational burdens of any cancer — largely because UV radiation damages DNA in a distinctive, trackable pattern. Duncan's research identified loss of 5-hydroxymethylcytosine as an epigenetic hallmark of melanoma (799 citations, Cell, 2012), one marker of how extensively the genome is disrupted. This high mutational load means melanoma cells display many abnormal proteins on their surface — proteins the immune system can theoretically recognize and attack.

The problem is that tumors learn to hide. They overexpress proteins like PD-L1 that bind to PD-1 receptors on T cells and deliver a "don't attack me" signal. CTLA-4 is a separate checkpoint that blunts T-cell activation even earlier, in lymph nodes. Checkpoint inhibitors block these suppressive signals and restore T-cell attack on tumor cells.

The major checkpoint inhibitor drugs

Anti-CTLA-4: Ipilimumab (Yervoy) was the first approved checkpoint inhibitor for melanoma (2011). It works earlier in the immune activation pathway but has higher rates of serious immune side effects.

Anti-PD-1: Nivolumab (Opdivo) and pembrolizumab (Keytruda) block the PD-1/PD-L1 interaction on activated T cells. They produce better tumor response rates and fewer serious side effects than ipilimumab alone.

Combination therapy: Nivolumab plus ipilimumab produces higher response rates than either drug alone — approximately 58% objective response rate in phase 3 trials for advanced melanoma — but significantly more grade 3–4 immune-related adverse events (approximately 59% of patients).

For patients whose tumors carry a BRAF V600E mutation (roughly 40–50% of melanomas), BRAF inhibitors can be combined with or sequenced before immunotherapy. Tsao's 2010 Cancer Research paper (741 citations) demonstrated that selective BRAF inhibition actually enhances T-cell recognition of melanoma cells without impairing lymphocyte function — providing the mechanistic rationale for this combination approach.

Skin side effects: the most common immune-related adverse event

Lacouture's 2020 JAAD review (444 citations) catalogued the full spectrum of checkpoint-related dermatologic adverse events. The skin is the organ most frequently affected — rash or pruritus occurs in roughly 30–40% of patients on anti-PD-1 therapy and up to 50% on combination therapy.

Common skin reactions:

• Maculopapular rash (flat and raised pink spots): Most frequent. Usually mild (grade 1–2), manageable with topical corticosteroids.
• Pruritus (itch): Can occur without visible rash. Antihistamines and topical steroids typically help.
• Vitiligo: White patches of depigmentation, particularly in melanoma patients. Paradoxically, vitiligo is associated with better tumor responses — immune activation against melanin-producing cells correlates with activity against melanoma cells.
• Lichenoid reactions: Flat-topped papules resembling lichen planus. May require oral steroids.

Serious but less common skin reactions:

• Bullous pemphigoid: Blistering autoimmune skin disease. Lacouture's 2016 Cancer Immunology Research paper (278 citations) described this distinct autoimmune bullous disorder emerging with PD-1/PD-L1 blockade — requiring high-dose steroids or immunosuppressants.
• Stevens-Johnson syndrome / toxic epidermal necrolysis: Rare but life-threatening. Triggers permanent discontinuation of the checkpoint inhibitor.

Side effects beyond the skin

The immune activation triggered by checkpoint inhibitors can affect nearly any organ:

• Gastrointestinal: Colitis (diarrhea, cramping) — more common with CTLA-4 blockade
• Pulmonary: Pneumonitis — ground-glass infiltrates on CT; can be severe
• Endocrine: Thyroiditis, hypophysitis (pituitary inflammation) — often permanent; requires hormone replacement
• Hepatic: Elevated liver enzymes — typically manageable with steroids
• Neurological: Rarely, encephalitis or peripheral neuropathy

Most immune-related adverse events are managed with systemic corticosteroids and, for severe cases, additional immunosuppressants. Critically, research has shown that treating these side effects with steroids does not appear to blunt the anti-tumor benefit of the checkpoint inhibitor.

When checkpoint inhibitors are not enough

Polsky's 2001 Nature paper (959 citations) identified inactivation of Apaf-1 — a key apoptosis effector — as a mechanism by which melanoma cells evade immune killing even when T cells recognize them. Duncan's 2017 Nature Communications paper (980 citations) showed that loss of antigen presentation machinery (beta-2-microglobulin mutations that disrupt MHC-I expression) is another common resistance pathway. These findings explain why some patients achieve dramatic initial responses and then relapse — and why ongoing trials are testing combinations of checkpoint inhibitors with therapies targeting these resistance mechanisms.

Staging, early detection, and when immunotherapy enters the picture

Rigel's early detection work in CA Cancer Journal (841 citations, 1985) and his 2010 review of the ABCD criteria's evolution (416 citations) frame the prevention side of this disease: when melanoma is caught at stage I or II, surgery alone is curative in most cases. Immunotherapy enters the conversation at stage III (regional lymph node spread) as adjuvant therapy to reduce recurrence risk, and at stage IV (distant metastasis) as the primary treatment approach.

Questions to ask your doctor

• Is my tumor BRAF-mutated, and if so, should I start with targeted therapy or immunotherapy first?
• What is the realistic chance that immunotherapy will produce a durable response in my specific situation?
• How will we monitor for immune-related side effects — what symptoms should prompt me to call your office immediately?
• If I develop a serious skin reaction, does stopping the checkpoint inhibitor mean I cannot restart it?
• Is combination nivolumab-ipilimumab likely to offer me a better chance than single-agent therapy given my current health status?
• Are there clinical trials at your institution studying resistance mechanisms or newer immunotherapy combinations?

The bottom line

Checkpoint inhibitors — particularly anti-PD-1 drugs and their combination with anti-CTLA-4 — have fundamentally changed the prognosis for advanced melanoma, converting a disease that was nearly always fatal within a year into one where long-term remission is achievable for a meaningful minority of patients. The trade-off is a real risk of immune-related side effects that can affect the skin, gut, lungs, and endocrine glands. A dermatologist experienced in oncology-related skin reactions, working in close coordination with your oncologist, is essential for catching these effects early and managing them without unnecessary interruption of your treatment.